Sitemap

Acura Pharmaceuticals, Inc.

Aversion® Technology

ACUROX™ Tablets

	Posters/ascpt_poster.pdf
	Study AP-ADF-101
	Study AP-ADF-102
	Study AP-ADF-103
	Study AP-ADF-104
	Study AP-ADF-107
	Study AP-ADF-111
	Extraction Study
	Phase III Clinical Trial
	Additional Studies

Patents and Trademarks

Market Opportunities

	Opioid Analgesic Markets
	NonOpioid Markets

Commercial Strategy

Culver Facility

Management Team

	Andrew D. Reddick
	Robert B. Jones
	Ron J. Spivey, Ph.D.
	Peter A. Clemens, CPA
	Robert A. Seiser, CPA
	James F. Emigh, R.Ph.
	Ronald L. Leech
	John G. Gilkay, P.E.
	Gregory A. Spinner

Board of Directors

	Richard J. Markham
	Andrew D. Reddick
	George K. Ross
	William G. Skelly
	William A. Sumner
	Immanuel Thangaraj
	Bruce F. Wesson

	PR 04/30/2008
	PR 04/24/2008
	PR 03/24/2008
	PR 03/05/2008
	PR 02/27/2008
	PR 01/31/2008
	PR 01/24/2008
	PR 12/10/2007
	PR 12/04/2007
	PR 11/02/2007
	PR 10/31/2007 (1)
	PR 10/31/2007 (2)
	PR 08/20/2007
	PR 08/09/2007
	PR 07/10/2007
	PR 06/19/2007
	PR 05/18/2007
	PR 05/04/2007
	PR 04/16/2007
	PR 04/02/2007
	PR 03/15/2007 (1)
	PR 03/15/2007 (2)
	PR 02/20/2007
	PR 12/11/2006

SEC Filings & Stock Price

	Reverse Split Letter.PDF
	SEC Reports/Acura Q1 2008 Form 10Q.pdf
	SEC Reports/Acura 2006 Form 10-K.pdf
	SEC Reports/Acura 2007 Form 10-K.pdf
	SEC Reports/Acura Q3 2007 Form 10Q.pdf
	SEC Reports/Acura Q2 2007 Form 10Q.pdf
	SEC Reports/Acura Q1 2007 Form 10Q.pdf

Employment Opportunities

Company Contacts

Forward - Looking Statements

Company Risk Factors

Ethics/Audit Charter

Privacy Policy & Disclaimer

Copyright © 1998-2008 Acura Pharmaceuticals. All rights reserved.